Products for Research Use Only

(E/Z) -Zotiraciclib

CAT: 0804-HY-15166-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15166-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
(E/Z) -Zotiraciclib ((E/Z) -TG02) is a potent inhibitor of CDK2, JAK2 and FLT3 with IC50s of 13, 73 and 56 nM, respectively. (E/Z) -Zotiraciclib effectively inhibits the proliferation of cancer cells, it can be used for the research of cancer[1][2].
CAS Number
937270-47-8
Product Name Alternative
(E/Z) -TG02; (E/Z) -SB1317
UNSPSC
12352005
Hazard Statement
H302
Target
CDK; FLT3; JAK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/e-z-zotiraciclib.html
Purity
99.96
Solubility
DMSO : 26.5 mg/mL (ultrasonic; warming)
Smiles
CN1CC2=CC(NC3=NC(C4=CC(OCC/C=C/C1)=CC=C4)=CC=N3)=CC=C2
Molecular Formula
C23H24N4O
Molecular Weight
372.46
Precautions
H302
References & Citations
[1]William AD, et al. Discovery of kinase spectrum selective macrocycle (16E) -14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1 (2,6) .1 (8,12) ]heptacosa-1 (25),2 (26),3,5,8 (27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kina|[2]Pasha MK, et al. Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6 (1) :33-42.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK2; JAK2